BURLINGAME, Calif. — Ten of the world’s leading biopharmaceutical companies announced the formation of a new non-profit corporation, Accumulus Synergy, which is intended to support interactions between industry and health authorities worldwide to enable real-time collaboration and data exchange, as well as data submission. Accumulus Synergy was formed on July 13, 2020, to develop a
NEW YORK — Bristol Myers Squibb and Forbius, a privately held, clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases, announced Monday that they have entered into a definitive agreement under which Bristol Myers Squibb will acquire Forbius. Forbius has developed a portfolio of highly selective and potent
PRINCETON, N.J. — In light of the COVID-19 pandemic, GRYT Health, a digital health company with a social purpose and creator of the Global Virtual Cancer Conference and the GRYT Health platform, and Bristol Myers Squibb have partnered to develop the COVID Advocacy Exchange, a virtual platform to unite patient advocacy organizations, patients, policy makers, healthcare
PRINCETON, N.J. — Bristol Myers Squibb has announced the presentation of data across its portfolio, aimed at addressing solid tumor and hematologic malignancies in 28 types of cancer, at the upcoming American Society of Clinical Oncology 2020 (ASCO20) Virtual Scientific Program, which will take place from May 29 to May 31, 2020. Presentations will feature
DEVENS, Mass. — Bristol-Myers Squibb has completed a major expansion of its biologics facility in Devens, Mass. The drug maker said the $280 million project will spur development of the company’s growing portfolio of biologics medicines. With the expansion, the 89-acre Devens campus received two new buildings: a biologics development building for designing processes for
